Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Biochemical Pharmacology

• Publication date

  1994-03-29

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0006-2952(94)90397-2PMID 8161354
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disposition of sumatriptan in laboratory animals and humans.

  1993cited by this paper
• Sumatriptan

  1992cited by this paper
• Xenobiotic oxidation catalyzed by aldehyde dehydrogenases.

  1989cited by this paper
• The Kinetics of 14C-GR43175 in Rat and Dog

  1989cited by this paper
• Interactions of monoamine oxidase with substrates and inhibitors

  1989cited by this paper
• Cytochrome P-450 enzymes and drug metabolism

  1987cited by this paper
• Testosterone metabolite profiles reveal differences in the spectrum of cytochrome P-450 isozymes induced by phenobarbitone, 2-acetylaminofluorene and 3-methylcholanthrene in the chick embryo liver.

  1986cited by this paper
• THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

  1964cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Defining the enzymes of xenobiotic metabolism – a forlorn hope?

  2025cites this paper
• Efficient Acyloxymethylation of Psilocin and Other Tryptamines Yielding ACOM Prodrugs for Psychedelic‐Assisted Therapy

  2025cites this paper
• Metabolism of sumatriptan revisited

  2023cites this paper
• Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions

  2022cites this paper
• Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crossover trials

  2021cites this paper
• Non-cytochrome P450 enzymes involved in the oxidative metabolism of xenobiotics: Focus on the regulation of gene expression and enzyme activity.

  2021cites this paper
• Investigation into MAO B–Mediated Formation of CC112273, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereospecific Oxidative Deamination of (S)-Enantiomer of Indaneamine (RP101075) by MAO B

  2021cites this paper
• Organic Cation Transporters in Health and Disease

  2020cites this paper
• Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions.

  2019cites this paper
• An iminium ion metabolite hampers the production of the pharmacologically active metabolite of a multikinase inhibitor KW‐2449 in primates: irreversible inhibition of aldehyde oxidase and covalent binding with endogenous proteins

  2018cites this paper
• [Research advances in non-P450-mediated drug oxidative metabolism].

  2017cites this paper
• Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans

  2017cites this paper
• Tranylcypromine in mind (Part I): Review of pharmacology.

  2017cites this paper
• Liabilities Associated with the Formation of "Hard" Electrophiles in Reactive Metabolite Trapping Screens.

  2017cites this paper
• OCT1 mediates hepatic uptake of sumatriptan and loss‐of‐function OCT1 polymorphisms affect sumatriptan pharmacokinetics

  2016cites this paper
• Special Section on Emerging Novel Enzyme Pathways in Drug Metabolism — Commentary Cytochrome P 450 and Non – Cytochrome P 450 Oxidative Metabolism : Contributions to the Pharmacokinetics , Safety , and Efficacy of Xenobiotics

  2016influential citation
• Permeation of sumatriptan succinate across human skin using multiple types of self-dissolving microneedle arrays fabricated from sodium hyaluronate

  2016cites this paper
• Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues

  2016cites this paper
• Cytochrome P450 and Non–Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics

  2016influential citation
• Improvement of transdermal delivery of sumatriptan succinate using novel water emulsion patch or self-dissolving microneedle array , and their in vitro and in vivo characterizations

  2015cites this paper
• Improvement of transdermal delivery of sumatriptan succinate using novel water emulsion patch or self-dissolving microneedle array, and their in vitro and in vivo characterizations

  2014cites this paper
• Development of a novel transdermal patch containing sumatriptan succinate for the treatment of migraine: in vitro and in vivo characterization

  2014cites this paper
• Profiling substrate specificity of two series of phenethylamine analogs at monoamine oxidase A and B.

  2014cites this paper
• Metabolism-guided drug design

  2013cites this paper
• Sumatriptan: treatment across the full spectrum of migraine

  2013cites this paper
• The Role of Biotransformation Studies in Reducing Drug Attrition

  2013cites this paper
• Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: Results from a randomized study in patients with migraine

  2013cites this paper
• Central Nervous System Drugs

  2012cites this paper
• In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict the in vivo clearance for compounds metabolized by monoamine oxidase

  2012cites this paper
• Oral Sumatriptan and Almotriptan – Delimiting the MAOI Effect

  2012cites this paper
• LC-ESI-MS/MS determination of in vivo metabolites of almotriptan in rat plasma, urine and feces: application to pharmacokinetics.

  2012cites this paper
• Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice

  2012cites this paper
• Metabolic Stability and Analogue‐Based Drug Discovery

  2012cites this paper
• A practical and direct comparison of intrinsic metabolic clearance of several non-CYP enzyme substrates in freshly isolated and cryopreserved hepatocytes.

  2012cites this paper
• Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.

  2011cites this paper
• Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy

  2011cites this paper
• Bioactivation II: Phase I (Non-P450)

  2011cites this paper
• Sumatriptan–naproxen fixed combination for acute treatment of migraine: a critical appraisal

  2010cites this paper
• Subcutaneous Sumatriptan Pharmacokinetics: Delimiting the Monoamine Oxidase Inhibitor Effect

  2010cites this paper
• Stereochemical studies on the novel monoamine oxidase B substrates (1R,6S)- and (1S,6R)-3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane.

  2008cites this paper
• Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions

  2008cites this paper
• Amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans: has the involvement of amine oxidases been neglected?

  2007cites this paper
• Diplotypes of the human serotonin 1B receptor promoter predict growth hormone responses to sumatriptan in abstinent alcohol-dependent men.

  2007cites this paper
• Disposition and metabolism of almotriptan in rats, dogs and monkeys

  2006cites this paper
• Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments

  2006cites this paper
• A novel and selective monoamine oxidase B substrate.

  2005cites this paper
• Sumatriptan Absorption from Different Regions of the Human Gastrointestinal Tract

  2004cites this paper
• Lékové interakce antidepresiv a lithia

  2004cites this paper
• Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan.

  2003cites this paper
• Non-P450 Mediated Oxidative Metabolism of Xenobiotics

  2003cites this paper
• The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).

  2003cites this paper
• Moclobemide: therapeutic use and clinical studies.

  2003cites this paper
• Reaction phenotyping in drug discovery: moving forward with confidence?

  2003cites this paper
• An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug.

  2003cites this paper
• Clinical Pharmacokinetics of Intranasal Sumatriptan

  2002cites this paper
• Molecular Cloning and Pharmacology of Porcine 5-Hydroxytryptamine Receptors Relevant to the Study of Antimigraine Drugs

  2002cites this paper
• Characterization of Sumatriptan-Induced Contractions in Human Isolated Blood Vessels Using Selective 5-HT1B and 5-HT1D Receptor Antagonists and In Situ Hybridization

  2002cites this paper
• The pharmacokinetics of sumatriptan when administered with norethindrone 1 mg/ethinyl estradiol 0.035 mg in healthy volunteers.

  2002cites this paper
• The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers.

  2002cites this paper
• Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization.

  2002cites this paper
• Frovatriptan: A Review of Drug‐Drug Interactions

  2002cites this paper
• Pharmacokinetics and Pharmacodynamics of the Triptan Antimigraine Agents

  2001cites this paper
• Metabolic (Hepatic) Clearance

  2001cites this paper
• Up to date on the use of triptans for child and adolescent migraine: state of the art

  2001cites this paper
• Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol.

  2001cites this paper
• Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors.

  2001cites this paper
• Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.

  2001cites this paper
• The Acute Treatment of Migraine with Frovatriptan

  2000cites this paper
• Migraine pharmacotherapy with oral triptans: a rational approach to clinical management

  2000cites this paper
• Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes.

  2000cites this paper
• Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.

  2000cites this paper
• Transformation Enzymes: Oxidative; Non-P450

  1999cites this paper
• A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6.

  1999cites this paper
• Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan.

  1999cites this paper
• In vitro metabolism of the M1-muscarinic agonist 5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine by human hepatic cytochromes P-450 determined at pH 7.4 and 8.5.

  1999cites this paper
• Fatal Cardiac Arrhythmia After Oral Sumatriptan

  1999cites this paper
• The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.

  1999cites this paper
• MAO — The Mother of all Amine Oxidases

  1998cites this paper
• Monoamine oxidases and related amine oxidases as phase I enzymes in the metabolism of xenobiotics.

  1998cites this paper
• Sumatriptan Contraindications and the Serotonin Syndrome

  1998cites this paper
• The Metabolism of Zolmitriptan

  1998cites this paper
• Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver.

  1998cites this paper
• In vivo properties of N-(2-aminoethyl)-5-halogeno-2-pyridinecarboxamide 18F- and 123I-labelled reversible inhibitors of monoamine oxidase B.

  1998cites this paper
• Zolmitriptan: a new acute treatment for migraine.

  1998cites this paper
• The role of non—P450 enzymes in drug oxidation.

  1997cites this paper
• Sumatriptan for migraine attacks in children

  1997cites this paper
• THE ABSORPTION, PHARMACODYNAMICS, METABOLISM AND EXCRETION OF 14C‐SUMATRIPTAN FOLLOWING INTRANASAL ADMINISTRATION TO THE BEAGLE DOG

  1997cites this paper
• Safety, Tolerability, and Pharmacokinetics of Sumatriptan Suppositories Following Single and Multiple doses in Healthy Volunteers

  1997cites this paper
• Safety, Tolerability, and Pharmacokinetics of Sumatriptan in Healthy Subjects Following Ascending Single Intranasal Doses and Multiple Intranasal Doses

  1997cites this paper
• The clinical pharmacokinetics of zolmitriptan

  1997cites this paper
• Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction.

  1997cites this paper
• Absorption, pharmacokinetics and metabolism of 14C-sumatriptan following intranasal administration to the rat.

  1996cites this paper
• [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].

  1996cites this paper
• Paroxetine treatment and the prolactin response to sumatriptan

  1996cites this paper
• The use of sumatriptan in patients on monoamine oxidase inhibitors

  1995cites this paper
• Inhibition of monoamine oxidase-B by 5H-indeno[1,2-c]pyridazines: biological activities, quantitative structure-activity relationships (QSARs) and 3D-QSARs.

  1995cites this paper
• Molecular basis of polymorphic drug metabolism

  1995cites this paper
• Sumatriptan (ImitrexR) Transport by the Human Placenta

  1995cites this paper